AstraZeneca PLC (NASDAQ: AZN) has reported Phase 3 VOLGA results showing that perioperative IMFINZI (durvalumab) combined with neoadjuvant enfortumab vedotin reduced the hazard of an event by 49% and the hazard of death by 42% in patients with muscle-invasive bladder cancer who were ineligible for or had refused cisplatin-based chemotherapy. Presented at the European Society for Medical Oncology Congress 2026 on October 24 and simultaneously published in the New England Journal of Medicine, the findings demonstrated statistically significant improvements in both event-free and overall survival compared with radical cystectomy-based standard care.
At two years, an estimated 64% of patients receiving the investigational regimen remained alive and event-free, compared with 45% in the control group. Overall survival at the same time point was 78% with the combination and 69% with the comparator, providing evidence that the observed reduction in cancer-related events was accompanied by a meaningful survival advantage.
The findings support AstraZeneca’s ongoing regulatory efforts to expand IMFINZI into a treatment setting where cisplatin-based chemotherapy may not be appropriate. The United States Food and Drug Administration granted Priority Review to the proposed regimen in September 2026, but the combination evaluated in VOLGA has not yet received approval. Its eventual clinical role will also be shaped by the availability of an already authorised perioperative pembrolizumab and enfortumab vedotin regimen.
What do the VOLGA results show about event-free survival in muscle-invasive bladder cancer?
VOLGA is a randomised, open-label, multicentre Phase 3 trial evaluating durvalumab-based treatment combinations in patients undergoing radical cystectomy for muscle-invasive bladder cancer. The trial randomised 695 patients across three groups, including regimens with and without tremelimumab and a surgery-based comparator arm. The October 2026 results focus on the comparison between perioperative durvalumab plus neoadjuvant enfortumab vedotin and radical cystectomy with or without approved adjuvant treatment.
The reported comparison included 233 patients receiving the durvalumab and enfortumab vedotin regimen and 229 patients in the control group. The investigational treatment involved three cycles of durvalumab and enfortumab vedotin before surgery, followed by nine cycles of durvalumab alone after surgery. The comparator group underwent radical cystectomy with or without approved postoperative therapy.
The primary endpoint was event-free survival, a composite measure that included disease progression, cancer recurrence, failure to undergo surgery under specified circumstances or death. This definition is important because the reported 49% hazard reduction does not refer exclusively to recurrence after successful surgery. It reflects the broader composite of clinically consequential events defined in the trial protocol.
At a planned interim analysis, the event-free survival hazard ratio was 0.51, with a 95% confidence interval of 0.38 to 0.67 and a p-value below 0.0001. Median event-free survival had not been reached in the investigational group, compared with 12.1 months in the control group. These results establish a statistically significant advantage for the tested regimen against its randomised comparator.
The trial also reported that 64% of combination-treated patients remained event-free at two years, compared with 45% of control patients. This 19-percentage-point difference provides a more direct view of the absolute separation between the treatment groups at a defined time point. The findings are relevant because preventing recurrence or progression after potentially curative treatment is a major objective in muscle-invasive bladder cancer.
However, the data do not establish that every component of the treatment sequence contributed equally to the observed benefit. Because patients received both preoperative combination treatment and postoperative durvalumab, the study evaluates the entire perioperative strategy rather than isolating the efficacy of neoadjuvant enfortumab vedotin or adjuvant durvalumab.
Why is the 42% reduction in the hazard of death particularly significant?
Overall survival provides an important independent assessment of the clinical value of a perioperative cancer regimen. Improving event-free survival may be valuable, but the strongest evidence of patient benefit emerges when delaying recurrence or progression is accompanied by longer survival. The VOLGA results demonstrated statistically significant improvements in both outcomes.
The overall survival hazard ratio was 0.58, with a 95% confidence interval of 0.40 to 0.83 and a p-value of 0.0027. This corresponds to a 42% lower hazard of death over the observation period among patients assigned to the investigational strategy. At the March 2, 2026 data cutoff, there had been 49 deaths in the combination group and 74 deaths in the comparator group.
Median overall survival had not been reached in either group, reflecting the maturity of the available follow-up and the proportion of patients remaining alive. The estimated two-year survival rates were 78% with the investigational regimen and 69% with standard care. These findings demonstrate a nine-percentage-point difference at the two-year assessment.
The study used prespecified interim statistical boundaries to evaluate significance. The reported p-values crossed the applicable thresholds for event-free and overall survival, supporting formal conclusions about both endpoints within the planned analysis framework. This distinguishes the findings from exploratory analyses where nominal p-values may not establish confirmatory evidence.
Continued follow-up will remain important because many patients were alive at the data cutoff. Additional observation could clarify the durability of the survival advantage and the frequency of late recurrence. Longer-term data may also provide information about treatment-related complications that emerge after completion of the perioperative regimen.
How does durvalumab plus enfortumab vedotin work around bladder cancer surgery?
Durvalumab is an immune checkpoint inhibitor that blocks PD-L1, a protein involved in suppressing antitumor immune responses. By interrupting this pathway, the medicine is intended to support immune recognition and destruction of cancer cells. Its clinical development has included several settings in which immunotherapy is administered before or after potentially curative treatment.
Enfortumab vedotin is an antibody-drug conjugate targeting Nectin-4, a cell-surface protein commonly expressed in urothelial carcinoma. The medicine delivers a microtubule-disrupting cytotoxic payload to targeted cells, providing a mechanism distinct from conventional platinum-based chemotherapy. Its established clinical activity has supported multiple regulatory approvals in urothelial cancer.
The combination brings together two different therapeutic mechanisms. Enfortumab vedotin targets tumor cells through antibody-mediated delivery of a cytotoxic medicine, while durvalumab seeks to enhance immune activity through PD-L1 blockade. The biological rationale involves potentially complementary effects on tumor destruction and antitumor immunity, although the trial does not independently prove a specific synergistic interaction.
The timing of treatment also matters. Neoadjuvant therapy is administered before surgery and may reduce tumor burden or address microscopic disease not detectable through imaging. Adjuvant therapy is given after surgery with the objective of reducing the risk that residual cancer cells contribute to recurrence.
VOLGA combines these approaches within a single treatment sequence. Patients received three cycles of the experimental combination before cystectomy and continued durvalumab following surgery. This allows treatment to begin while the primary tumor remains present and continue during the postoperative period when recurrence risk remains relevant.
The strategy is especially important for patients unable to receive cisplatin-based chemotherapy. Such patients may have kidney impairment, other medical conditions or circumstances that make conventional platinum-based neoadjuvant treatment unsuitable. A non-cisplatin perioperative regimen could address an important clinical need, provided its efficacy and safety support use in the intended population.
What does the safety profile reveal about treatment before major bladder surgery?
AstraZeneca reported that the safety profile of durvalumab plus enfortumab vedotin was consistent with the known characteristics of the individual medicines. The company identified no new safety signals in the disclosed analysis and reported that patient-reported quality of life was maintained after surgery among patients receiving the investigational regimen. These findings provide supportive information but do not eliminate concerns associated with combining two active systemic therapies.
Grade 3 or 4 adverse events from any cause occurred in 64% of patients receiving the investigational regimen, compared with 44% in the comparator group. This 20-percentage-point difference indicates a substantial additional burden of severe adverse events within the combination treatment pathway. The figures encompass events from any cause rather than exclusively treatment-attributed toxicity.
Durvalumab carries established risks of immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis and endocrine disorders. Enfortumab vedotin has its own clinically important toxicity profile, including skin reactions, peripheral neuropathy and hyperglycaemia. The precise frequency of each adverse event in VOLGA requires examination of the complete trial safety dataset rather than extrapolation from historical studies.
The perioperative setting introduces additional considerations because systemic treatment must be coordinated with major surgery. Toxicity leading to treatment interruption, delayed cystectomy or impaired recovery could undermine the intended clinical benefit. Consequently, the ability to deliver neoadjuvant treatment without compromising surgery is an important component of the overall benefit-risk assessment.
The trial’s event-free survival definition includes certain failures to proceed to radical cystectomy, making the treatment pathway itself relevant to efficacy assessment. Detailed surgical outcomes, treatment completion rates and postoperative complications will help clarify how reliably the regimen can be implemented. These operational measures may influence clinical adoption even when the survival results are favourable.
Patient-reported quality-of-life findings are also relevant because radical cystectomy can have substantial effects on urinary, sexual and physical functioning. Maintaining quality of life after surgery is encouraging, but the company announcement does not provide enough detail to establish differences across individual quality-of-life domains. A fuller assessment will require the underlying instruments, response rates and longitudinal findings.
How does VOLGA compare with the approved pembrolizumab and enfortumab vedotin regimen?
The most important competitive consideration is that durvalumab plus enfortumab vedotin would not enter an untreated regulatory market if approved. In November 2025, the United States Food and Drug Administration authorised pembrolizumab with enfortumab vedotin as neoadjuvant treatment followed by postoperative therapy for adults with muscle-invasive bladder cancer who were ineligible for cisplatin. The approval was supported by the randomised KEYNOTE-905/EV-303 trial.
That trial demonstrated statistically significant improvements in event-free and overall survival compared with surgery alone. The reported event-free survival hazard ratio was 0.40, while the overall survival hazard ratio was 0.50. These findings established a treatment option combining enfortumab vedotin with a different immune checkpoint inhibitor in a clinically relevant patient population.
The approved indication was further expanded in July 2026 to include adults with muscle-invasive bladder cancer who were candidates for cystectomy, following additional evidence from KEYNOTE-B15/EV-304. This expansion broadened the commercial and clinical reach of the pembrolizumab-based regimen beyond the original cisplatin-ineligible population.
VOLGA therefore presents a potential alternative involving PD-L1 blockade rather than PD-1 blockade, combined with the same antibody-drug conjugate. However, the available evidence does not establish that one combination is more effective than the other. Differences between the trials, including eligibility criteria, treatment schedules, patient characteristics and follow-up, prevent reliable superiority claims based on isolated hazard ratios.
The eventual positioning of durvalumab plus enfortumab vedotin will depend on the authorised indication, safety, treatment schedule and clinician experience. Payers and healthcare systems may also consider costs and procurement arrangements when evaluating alternative regimens with overlapping intended populations.
AstraZeneca faces an additional challenge because it must demonstrate the commercial relevance of introducing another checkpoint inhibitor into a setting where an established combination has already received approval. The VOLGA survival results provide a credible clinical foundation, but competitive differentiation will require more than demonstrating benefit against historical surgery-based care.
How does VOLGA extend the earlier NIAGARA success for IMFINZI?
AstraZeneca already has an approved perioperative IMFINZI regimen for muscle-invasive bladder cancer. In March 2025, the United States Food and Drug Administration approved durvalumab with gemcitabine and cisplatin before surgery, followed by durvalumab alone after radical cystectomy. The decision was based on the Phase 3 NIAGARA trial in patients eligible for cisplatin-based treatment.
NIAGARA demonstrated a statistically significant improvement in event-free survival, with a hazard ratio of 0.68, and an overall survival hazard ratio of 0.75. These findings established the role of durvalumab in a perioperative strategy involving conventional platinum chemotherapy. The approved regimen provided AstraZeneca with an existing presence in muscle-invasive bladder cancer before the new VOLGA disclosure.
The two trials address different treatment circumstances. NIAGARA focused on patients suitable for cisplatin-based chemotherapy, whereas VOLGA enrolled patients who were ineligible for or refused cisplatin. The treatment combinations also differ because VOLGA substitutes enfortumab vedotin for conventional platinum chemotherapy in the preoperative regimen.
These distinctions make VOLGA more than a repetition of the earlier durvalumab development programme. The findings investigate whether the checkpoint inhibitor can support a perioperative strategy for patients who could not or would not receive the chemotherapy backbone used in NIAGARA. If authorised, the regimen would extend AstraZeneca’s therapeutic offering across a broader range of clinical circumstances.
However, the results should not be interpreted as evidence that enfortumab vedotin is superior to cisplatin chemotherapy when combined with durvalumab. No such direct randomised comparison was established by the reported analysis. Treatment selection would remain dependent on the approved indication, patient eligibility and available clinical evidence.
What does FDA Priority Review mean for AstraZeneca’s bladder cancer application?
In September 2026, the Food and Drug Administration granted Priority Review to the proposed perioperative regimen of durvalumab plus neoadjuvant enfortumab vedotin for patients with muscle-invasive bladder cancer who were ineligible for or refused cisplatin-based chemotherapy. The regulatory action followed review of the application supported by VOLGA data. Priority Review shortens the agency’s target review period but does not establish that the application will be approved.
The regulator will assess the full efficacy and safety evidence, including the event-free survival definition, overall survival findings, treatment exposure and the ability of patients to proceed through surgery. Particular attention may be given to whether the efficacy benefit justifies the additional frequency of severe adverse events observed in the investigational arm. Manufacturing, labelling and risk-management requirements are also part of the approval process.
The availability of an approved pembrolizumab and enfortumab vedotin combination introduces a practical context for regulatory and clinical evaluation. While the VOLGA trial’s statistical findings are based on its own randomised comparator, clinicians will need to understand how any newly authorised regimen fits alongside treatments already available in the same broad disease setting.
The unreported results from VOLGA’s separate tremelimumab-containing experimental arm should not be inferred from the findings presented for durvalumab and enfortumab vedotin alone. The three-arm trial evaluated distinct strategies, and evidence from one experimental arm does not establish the efficacy of the other. Each comparison requires its own properly interpreted results.
If approval is granted, the extent of the authorised indication and applicable warnings will be important determinants of commercial uptake. AstraZeneca would then need to support oncology and urology teams in delivering a treatment sequence that spans preoperative therapy, radical cystectomy and postoperative immunotherapy.
What will determine whether VOLGA changes muscle-invasive bladder cancer treatment?
The VOLGA findings demonstrate that perioperative durvalumab with neoadjuvant enfortumab vedotin improved event-free and overall survival compared with surgery-based care in the population studied. The results are supported by statistically significant effects and clinically interpretable differences in two-year outcomes. Their principal limitation is not the strength of the randomised comparison but the uncertainty surrounding how the regimen will fit alongside an already approved alternative.
Detailed adverse-event, treatment completion and surgical outcome data will help clinicians assess whether the additional treatment burden is manageable across different patient populations. Longer follow-up will establish whether the survival advantage remains durable beyond the interim analysis. These findings will also inform discussions about how the regimen can be delivered within multidisciplinary bladder cancer care.
The regulatory decision will determine whether AstraZeneca can commercialise the combination for the proposed indication. Its commercial success will then depend on whether clinicians, hospitals and payers identify a practical role for durvalumab alongside established perioperative treatment options.
For AstraZeneca, VOLGA broadens the clinical evidence supporting IMFINZI in muscle-invasive bladder cancer, while the existing competitive landscape makes clinical differentiation particularly important. The trial establishes a meaningful survival benefit over its control strategy, but the next test will be converting that evidence into an approved and clinically useful treatment option in a market where the standard of care has already advanced.
